Selected Grants
External Quality Assurance Program Oversight Laboratory (EQAPOL)
ResearchClinical Data Manager · Awarded by National Institute of Allergy and Infectious Diseases · 2024 - 2031CEPI QAU
ResearchProduct Manager · Awarded by Imperial College London · 2025 - 2029BNT165-02
ResearchProject Manager · Awarded by BioNTech SE · 2025 - 2028HIV Vaccine Trials Network Laboratory Center
ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Center · 2022 - 2027Tuberculosis (M72) Immune Correlates
ResearchQuality Management Coordinator · Awarded by Bill and Melinda Gates Medical Research Institute · 2025 - 2026CIVICs Component A Year 7 - Option 6
ResearchProgram Manager · Awarded by National Institutes of Health · 2019 - 2026Antibody Dynamics for BNT165b1
ResearchClinical Data Manager · Awarded by BioNTech SE · 2023 - 2026Immunogenicity (Serum IgG)
ResearchProgram Manager · Awarded by Uvax Bio, LLC · 2024 - 2026Surgical Critical Care Initiative (SC2I): Civilian application of military decision support tools for critically injured patients.
ResearchQA Liaison · Awarded by Henry M. Jackson Foundation · 2021 - 2026CoVPN 3008 TB Study
ResearchQuality Management Coordinator · Awarded by Fred Hutchinson Cancer Center · 2025 - 2025IMPAACT 2042
ResearchQuality Management Coordinator · Awarded by Johns Hopkins University · 2025 - 2025CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection
ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years
ResearchProject Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024Moderna mRNA1275 P205 Trial Neutralizing Antibody Assessment
ResearchProgram Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine
ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Center · 2022 - 2023A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled, Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effe
ResearchClinical Data Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
ResearchClinical Data Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023Neutralizing Antibody Response Assessment for a Phase 2/3 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccin
ResearchProgram Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older
ResearchData Manager · Awarded by Seattle Cancer Care Alliance · 2022 - 2022CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
ResearchProgram Manager · Awarded by Seattle Cancer Care Alliance · 2022 - 2022A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A
ResearchClinical Data Manager · Awarded by Moderna Therapeutics, Inc. · 2021 - 2022HVTN Laboratory Center: Phase 1 PF
ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
ResearchProgram Manager · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022External Relationships
- Costco
- HONEYWELL INTERNATIONAL INC
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.